<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205929</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 20645</org_study_id>
    <nct_id>NCT04205929</nct_id>
  </id_info>
  <brief_title>Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users</brief_title>
  <official_title>Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: a Randomized Clinical Trial of Curcumin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to study the effects of curcumin, the active ingredient in the spice&#xD;
      turmeric, on the irregular bleeding experienced by women who use the contraceptive implant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a randomized, double blind placebo-controlled clinical trial&#xD;
      over a 30-day reference period for treatment of women experiencing bothersome bleeding while&#xD;
      using the etonogestrel (ENG) contraceptive implant. The primary outcome of the study will be&#xD;
      the total number of amenorrhea days in a 30-day reference period. The study has a number of&#xD;
      secondary outcomes (see study objectives) focused around the efficacy of oral curcumin to&#xD;
      stop bleeding/spotting and for how long.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo-controlled Computer-generated randomization schema</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of amenorrhea days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of bleeding free days in the 30-day reference period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of bleeding/spotting days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of days with bleeding or spotting in the 30-day reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of consecutive bleeding-free days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Number of consecutive days with no bleeding after beginning treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of spotting days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of days with spotting in the 30-day reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of bleeding days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of days with bleeding in the 30-day reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) to stop bleeding</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Number of days for bleeding to stop after beginning treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction with bleeding pattern as assessed by VAS</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Level of patient satisfaction with bleeding pattern as measured by Visual Analog Scale (VAS). The scale ranges from 0 (lowest possible satisfaction) to 100 (highest possible satisfaction).</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of participants who intend to continue use of implant</measure>
    <time_frame>Day 30</time_frame>
    <description>Percentage of participants who are continuing implant use or anticipate implant continuation, evaluated at the end of study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Bleeding</condition>
  <condition>Implants</condition>
  <condition>Breakthrough Bleeding</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding</description>
    <arm_group_label>Curcumin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Women 15-45 years of age&#xD;
&#xD;
          -  Currently using the ENG implant for at least 30 days and use proven on exam (palpation&#xD;
             of implant at screening visit)&#xD;
&#xD;
          -  Willing to continue using the implant for at least 30 days from study enrollment&#xD;
&#xD;
          -  &gt;7 days of continuous bleeding/spotting in the last 30 days, OR 2 or more episodes of&#xD;
             bleeding/spotting in the last 30 days.&#xD;
&#xD;
          -  Access to a reliable cell phone and must be willing to receive and respond to a daily&#xD;
             text or email message to assess bleeding and use of study drug&#xD;
&#xD;
          -  Negative gonorrhea/chlamydia screening performed at screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Postpartum within six months&#xD;
&#xD;
          -  Post-abortion within six weeks&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Currently breast-feeding (to be eligible, must be 4-6 weeks from cessation of&#xD;
             breastfeeding)&#xD;
&#xD;
          -  Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant&#xD;
&#xD;
          -  Bleeding dyscrasia&#xD;
&#xD;
          -  Anticoagulation use&#xD;
&#xD;
          -  Active cervicitis&#xD;
&#xD;
          -  Allergy to curcumin or turmeric&#xD;
&#xD;
          -  History of venous thromboembolism&#xD;
&#xD;
          -  Current or past breast or uterine malignancy&#xD;
&#xD;
          -  Use of P450 pathway inducing drug&#xD;
&#xD;
          -  Implant is due to be switched out in 2 months or less from enrollment&#xD;
&#xD;
          -  Currently using oral contraceptives in addition to implant (to be eligible, needs to&#xD;
             have a 4-6 week washout period)&#xD;
&#xD;
          -  Prior pregnancy occurred while Nexplanon/Implanon was in place&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Women's Health Research Unit Department of OB/Gyn</last_name>
    <phone>503-494-3666</phone>
    <email>whru@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison B Edelman, MD, MPH</last_name>
      <phone>503-494-5949</phone>
      <email>edelmana@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Alison B Edelman, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>Professor OB/Gyn</investigator_title>
  </responsible_party>
  <keyword>Contraceptive implant</keyword>
  <keyword>Irregular bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

